The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.
December 13, 2024 06:21 ET
|
Pharma Equity Group A/S
Bestyrelsens beslutning om ny eksekveringsstrategi og prioritering af kliniske områder i Reponex Pharmaceuticals A/S. 13. december 2024Selskabsmeddelelse nr. 32 Pharma Equity Group...
The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.
December 13, 2024 06:21 ET
|
Pharma Equity Group A/S
The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S. December 13, 2024Announcement No. 32 Pharma Equity Group...
Martin Engell-Rossen skal fremover være kabinetschef for Danmarks nye EU-kommissær Dan Jørgensen i Bruxelles og udtræder derfor af bestyrelsen i Pharma Equity Group A/S
November 29, 2024 01:45 ET
|
Pharma Equity Group A/S
29 november 2024Meddelelse nr. 31 Martin Engell-Rossen skal fremover være kabinetschef for Danmarks nye EU-kommissær Dan Jørgensen i Bruxelles og udtræder derfor af bestyrelsen i Pharma...
Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S
November 29, 2024 01:45 ET
|
Pharma Equity Group A/S
29 November 2024Announcement No. 31 Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of...
Konsolideret delårsrapport 1. januar – 30. september 2024
November 15, 2024 02:33 ET
|
Pharma Equity Group A/S
Konsolideret delårsrapport 1. januar – 30. september 2024 Selskabsmeddelelse nr. 30 – 15. november 2024 Hovedpunkter fra delårsrapporten for perioden 1. januar - 30. september 2024 ...
Consolidated Interim report 1 January – 30 September 2024
November 15, 2024 02:33 ET
|
Pharma Equity Group A/S
Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 – November 15, 2024 Key points from the Q1-Q3-2024 report (period 1 January - 30 September 2024) On 15...
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har opnået patentbeskyttelse i Japan på behandling af colorectal cancer med RNX-051.
October 23, 2024 04:28 ET
|
Pharma Equity Group A/S
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har opnået patentbeskyttelse i Japan på behandling af colorectal cancer med RNX-051. 23. oktober 2024 Selskabsmeddelelse nr. 29 ...
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
October 23, 2024 04:28 ET
|
Pharma Equity Group A/S
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051. October 23, 2024Company Announcement...
Storaktionærmeddelelse - Pharma Equity Group A/S
October 14, 2024 02:17 ET
|
Pharma Equity Group A/S
Storaktionærmeddelelse - Pharma Equity Group A/S 14. oktober 2024Selskabsmeddelelse nr. 28 Pharma Equity Group A/S har i henhold til kapitalmarkedslovens § 38 modtaget storaktionærmeddelelse om,...
Major shareholder announcement - Pharma Equity Group A/S
October 14, 2024 02:17 ET
|
Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S 14 October 2024Announcement No. 28 Pharma Equity Group A/S has, in accordance with section 38 of the Capital Markets Act, received major...